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Background: Cognitive behavior therapy (CBT) is regarded as an effective treatment for social anxiety disorder
(SAD) in Europe and North America. Individual CBT might be acceptable and effective for patients with SAD even in
non-Western cultures; therefore, we conducted a feasibility study of individual CBT for SAD in Japanese clinical
settings. We also examined the baseline predictors of outcomes associated with receiving CBT.
Methods: This single-arm trial employed a 14-week individual CBT intervention. The primary outcome was the
self-rated Liebowitz Social Anxiety Scale, with secondary measurements of other social anxiety and depressive
severity. Assessments were conducted at baseline, after a waiting period before CBT, during CBT, and after CBT.
Results: Of the 19 subjects screened, 15 were eligible for the study and completed the outcome measures at
all assessment points. Receiving CBT led to significant improvements in primary and secondary SAD severity
(ps < .001). The mean total score on the Liebowitz Social Anxiety Scale improved from 91.8 to 51.7 (before CBT to
after CBT), and the within-group effect size at the end-point assessment was large (Cohen’s d = 1.71). After CBT,
73% of participants were judged to be treatment responders, and 40% met the criteria for remission. We found no
significant baseline predictors of those outcomes.
Conclusion: Despite several limitations, our treatment—which comprises a 14-week, individual CBT program—seems
feasible and may achieve favorable treatment outcomes for SAD in Japanese clinical settings. Further controlled trials
are required in order to address the limitations of this study.
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Social anxiety disorder (SAD; also known as social pho-
bia) is characterized by fear of social situations involving
performance or interaction [1]. SAD is one of the most
prevalent psychiatric disorders in developed and devel-
oping countries [2] and is associated with substantial co-
morbidity (like many other anxiety and depressive
disorders), functional disability (including social and oc-
cupational impairment), low health-related quality of life,
and economic burden [3-5].
Pharmacotherapy and psychotherapy have been
recommended as the first-line treatments for SAD [6-8].
In terms of pharmacotherapy, a growing database of ran-
domized, controlled trials demonstrates that selective
serotonin reuptake inhibitors (SSRIs) are effective and
well tolerated [8]. In psychotherapy, cognitive behavioral
therapy (CBT) has consistently been shown to be effect-
ive in randomized, controlled trials [9]. While no clear
evidence has shown that the combination of SSRIs and
CBT is more effective than single-modality treatment
[10,11], CBT has a number of potential advantages over
pharmacotherapy in the treatment of anxiety disorder:
longer effects, fewer adverse effects, smaller relapse
rates, and greater acceptability [12-14]. Pharmacotherapy
has disadvantages such as more side effects and higher
rates of relapse with the discontinuation of medication
[15,16].
CBT was introduced into Japanese psychiatry in the
late 1980s, and awareness of the effectiveness of CBT
has spread, not only among professionals and academics
but also among the general public. In April 2010, CBT
for mood disorders (beyond that for anxiety disorders)
began to be covered by Japan’s national health insurance
system. Nevertheless, a recent nationwide survey in
Japan demonstrated that only 28% of medical facilities
reported being able to conduct any form of psychother-
apy satisfactorily [17] because of the limited availability
of specialized practitioners. Only SSRIs (fluvoxamine
and paroxetine) have been established as first-line treat-
ments for Japanese patients with SAD as of 2012. It is
therefore necessary to investigate whether CBT can
achieve favorable treatment outcomes in Japanese SAD
patients.
Previous reports about the effectiveness of CBT mostly
came from Europe and North America, and CBT models
and treatment components were developed in Western
cultures with theoretical orientations typically constrained
by Western conceptualizations of SAD. Cultural factors
may be especially relevant to SAD pathology. For example,
taijin-kyofu-sho (in Japanese, taijin means “interpersonal,”
kyofu means “fear,” and sho means “syndrome”), which is
listed in the appendix to DSM-IV, is said to be a culture-
bound syndrome that is unique to East Asia. Although
fear of interpersonal relations has been considered aculture-bound syndrome [18-20], it can also be classified
under existing categories in the DSM-IV-TR [21-23]. The
notion that fear of interpersonal relations is purely a
culture-bound syndrome does not always hold true. Des-
pite differences between the conceptualizations of SAD
and taijin-kyofu-sho, patients suffering from SAD in differ-
ent parts of the world share many features in common,
and similar assessments and treatments have been utilized
across the world [24].
Only Chen and colleagues [25-27] showed that group
CBT can bring about a similar degree of symptom re-
duction for Japanese patients as for Western patients
with SAD. However, no study has tested the effective-
ness of individual CBT for SAD in Japan. It is necessary
to investigate whether individual CBT can achieve favor-
able treatment outcomes in Japanese patients with SAD,
because some recent studies from Europe and North
America have suggested that individual CBT is more ef-
fective than group CBT [28,29]. In addition, SAD has
commonly been found to be highly comorbid with other
Axis-I disorders, such as depression, bipolar disorder,
and other anxiety disorders. Therefore, it is also import-
ant to understand how comorbidity and other clinical
demographics affect treatment outcomes for SAD in
clinical settings.
Thus, the purposes of this study are to report the pre-
liminary outcomes of an individual CBT program for
SAD in Japanese clinical settings and to examine the
baseline predictors of the short-term outcomes associ-
ated with receiving CBT. The hypothesis is that individ-
ual CBT will be associated with decreased SAD severity
in Japanese clinical settings and achieve comparable ef-
fectiveness to applications reported in Western settings.Methods
Participants
The criteria for inclusion in this study were a primary diag-
nosis of SAD according to the DSM-IV, age of 18–65 years,
and at least moderately severe SAD (on the basis of a
Liebowitz Social Anxiety Scale [LSAS] score ≥ 50) [30,31].
Because Sugawara et al. (2012) reported that the mean
total LSAS score was 42.4 (average SD = 27.5) in healthy
Japanese community-dwelling subjects (N = 929) [32], we
set a cutoff score of 50 on the LSAS for screening patients
as suffering from moderate–severe symptoms of SAD. So
that the study population would reflect routine clinical
practice, comorbid diagnoses were permitted if clearly sec-
ondary (i.e., the SAD symptoms were both the most severe
and the most impairing).
The exclusion criteria were psychosis, pervasive devel-
opmental disorders/mental retardation, autism spectrum
disorders (Autism Spectrum Quotient ≥ 32) [33], current
high risk of suicide, substance abuse or dependence in
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stable medical condition, pregnancy, or lactation.
All patients were evaluated by a psychiatrist using the
Structured Clinical Interview for Axis I Disorders
(SCID-I) [34]. All patients were also screened for autism
spectrum disorder with the Autism Spectrum Quotient
[33] and the avoidant personality disorder section of the
SCID–II [35], because those measures show some over-
lap with social-anxiety features and cannot be screened
using SCID-I. Treatment history was confirmed by the
prescribing clinician and by chart review.
Interventions
The CBT intervention was conducted in 14 weekly 90-
minute sessions. Because the CBT model developed by
Clark and Wells [36] has shown excellent treatment out-
comes [28,29,37-39], our CBT program is based on the
model of Clark and Wells. The main steps in treatment
were as follows The main steps in treatment were as fol-
lows: (a) developing an individualized version of the
cognitive-behavioral model of SAD; (b) conducting role-
play–based behavioral experiments with and without
safety behaviors; (c) restructuring distorted self-imagery
using videotape feedback; (d) practicing external focus and
shifting attention; (e) behavioral experiments to test nega-
tive beliefs; (f) modifying problematic pre- and post-event
processing; (g) discussing the differences between self-
beliefs and other people’s beliefs (reflected in survey re-
sults); (h) dealing with the remaining assumptions
(schema work); (i) rescripting early memories linked to
negative images in social situations; and (g) preventing re-
lapse. Homework was assigned after every session.
Therapist and quality control
The CBT intervention was delivered by 6 therapists (3
clinical psychologists, 1 nurse, 1 psychiatrist, and 1 psychi-
atric social worker) who were experienced in the use of
CBT for anxiety disorders and had completed the CBT
training program at Chiba University (Chiba Improving
Access for Psychological Therapies project). To check ad-
herence to the protocol and assist with planning future
sessions for each treatment, all therapists attended weekly
group supervision sessions with other therapists and
supervision sessions with a senior supervisor (ES). The se-
nior supervisor also checked the quality of their CBT on
the basis of the Cognitive Therapy Scale-Revised [40].
Outcomes
The primary outcome measure was self-reported symp-
toms of social anxiety, as measured on the LSAS [30],
which is the most frequently used scale for the assess-
ment of SAD. To assure comparability with previous
CBT studies using the model of Clark and Wells, pa-
tients also completed additional self-report measures ofSAD severity: the Social Phobia Scale/Social Interaction
Anxiety Scale (SPS/SIAS) [41], the Fear of Negative
Evaluation Scale (FNE) [42], and the Fear Question-
naire – Social Phobia subscale (FQ-SP) [43]. Good reli-
ability and validity of the Japanese versions have been
reported for the LSAS, SPS, SIAS, and FNE [44-46].
Study design
This study was conducted as a single-arm, open trial to re-
port the preliminary outcomes and the feasibility of a CBT
intervention for SAD in Japanese clinical settings. Because
this study was the first trial to employ an individual CBT
intervention for SAD in East Asia (particularly in Japan), a
single-arm trial examining baseline predictors rather than
an efficacy trial is an appropriate design [47].
After enrolling in the study, patients were placed on a
2-week waiting period to establish the baseline stability
of their symptoms. At the end of the waiting period, the
patients received a CBT intervention for 14 weeks. Con-
comitant medications were permitted if the dose had
been stable for at least 4 weeks prior to study entry and
remained stable throughout the study. Assessments were
conducted at baseline (week 0), pre-CBT (before session
1/week 2), mid-CBT (after session 7/week 9), and post-
CBT (after session 14/week 16) time points.
This study was conducted at the psychiatric outpatient
section at Chiba University Hospital and was performed
in compliance with the Helsinki Declaration. The study
protocol was approved by the Ethics Committee of the
Chiba University Graduate School of Medicine (Refer-
ence number: 1216) and was registered in the national
UMIN Clinical Trials Registry (ID: UMIN000005897).
Statistical analysis
The analysis was by intention-to-treat, and the last
obtained data points for non-completers (because of ad-
verse events, lack of compliance, etc.) were carried for-
ward until the endpoint assessment. All statistical tests
were two-tailed, and an α of .05 was employed. All of
the data were analyzed using IBM SPSS Statistics for
Windows, Version 20.0 (IBM, Armonk, New York,
USA).
The baseline, pre-CBT, mid-CBT and post-CBT scores
were analyzed between groups with single-factor (time)
repeated-measures analyses of variance (ANOVAs) using
Greenhouse–Geisser correction. Pairwise differences
were measured using paired t-tests with Bonferroni cor-
rection to control for Type I error. The adjusted α value
was α = .05 / 4 = .013.
The mean changes in our primary outcome measure
(LSAS) were calculated among patients showing both
symptomatic response and remission. We established
the following threshold for response and remission [48]:
treatment-responder status was defined as a 31%-or-
Yoshinaga et al. BMC Research Notes 2013, 6:74 Page 4 of 8
http://www.biomedcentral.com/1756-0500/6/74greater reduction in LSAS score over the course of treat-
ment, and remission was defined as a score of ≤ 36 on
the LSAS. Moreover, patients who met the remission cri-
teria were confirmed to no longer meet the criteria for
SAD diagnosis using SCID-I interviews conducted by a
skilled psychiatrist who was not a CBT therapist.
Moreover, the magnitude of the treatment effect was
determined as the effect size ([Mpre − CBT −Mpost −CBT]/
SDpre −CBT) for each scale (LSAS, SPS, SIAS, FNE, and
FQ-SP). According to Cohen [49], effect sizes are cate-
gorized as follows: small (.20–.49), medium (.50–.79),
and large (≥ .80). Effect sizes reported in previous stud-
ies were calculated by different methods for various out-
come measures. For a direct comparison among
different CBT studies, we recalculated the effect sizes for
each study based on these measures of SAD severity
using the formula [(Mpre − CBT −Mpost −CBT)/SDpre − CBT].
Finally, in order to elucidate the baseline predictors of
treatment outcomes, multiple regression analyses were
conducted with post-treatment LSAS scores as a depen-
dent variable and the baseline demographic and clinical
variables (gender, age, SAD subtype, presence of comorbid
major depressive disorder, presence of another comorbid
anxiety disorder, presence of avoidant personality disorder,
age of onset, duration of SAD, employment status, marital
status, educational status, use of medication, presence ofFigure 1 CONSORT participants’ flow diagram. Abbreviations: LSAS, Liebresistance to antidepressants) as independent variables
while controlling for baseline LSAS scores.
Results
Treatment acceptability by the therapists
All of the participating therapists participated in the CBT
training program (Chiba Improving Access for Psycho-
logical Therapies project) for 2 years and were able to ad-
here to the treatment protocol under weekly supervision.
The mean CTS-R rating (adjusted for caseload) was 36.1
(on the basis of 15 randomly selected sessions; average
SD = .39), which is greater than the threshold of compe-
tence expected in UK CBT training programs [40].
Baseline data
Participants were recruited according to the Consoli-
dated Standards of Reporting Trials (CONSORT) guide-
lines, as presented in Figure 1. Of the 19 subjects
screened, 15 were eligible for the study criteria and re-
ferred to the study. After enrolling in the study, no pa-
tient dropped out throughout the study. Table 1 shows
the baseline demographic and clinical variables of the 15
patients enrolled in this study. The participants included
12 women (80%), and the patients’ mean age was 29.9
years. All participants met the principal DSM-IV diag-
nostic criteria for SAD. Additional Axis I diagnoses forowitz Social Anxiety Scale; CBT, Cognitive Behavioral Therapy.
Table 1 Baseline demographic and clinical characteristics
(N = 15)
Variable Value
Gender, female, N (%) 12 (80)
Age, years, Mean (SD) 29.9 (9.2)
Subtype, generalized, N (%) 13 (87)














Age of onset, years, Mean (SD) 17.6 (8.3)
Duration of SAD, years,
Mean (SD)
12.5 (9.8)
Employment status, N (%) Employed full-time 3 (20)
Full-time student 6 (40)
Part-time/homemaker 2 (13)
Unemployed 4 (26)





Junior high school 2 (13)
High school 7 (44)
<3 years of college/
university
3 (20)
≥3 years of college/
university
3 (20)
Length of education, years,
Mean (SD)
13.7 (1.8)
Current medication, N (%) Benzodiazepines 5 (33)
Antidepressants 5 (33)
Both BZ and AD 3 (20)




1: failure to respond to antidepressants: at least one SSRI was inadequate
despite maximum dose and treatment duration of at least 12 weeks.
Abbreviations: SAD, Social Anxiety Disorder; BZ, Benzodiazepines;
AD, Antidepressants.
Yoshinaga et al. BMC Research Notes 2013, 6:74 Page 5 of 8
http://www.biomedcentral.com/1756-0500/6/74the patients included major depressive disorder (53%)
and other anxiety disorders (e.g., panic disorder with
agoraphobia; 7%). Other demographic and clinical vari-
ables of the participants are shown in Table 1.
Treatment outcomes
Table 2 presents the mean baseline, pre-CBT, mid-CBT,
and post-CBT raw scores for the primary and secon-
dary outcome measures. Single-factor repeated-measuresANOVAs showed significant main effects of time on all
outcome measures after the completion of treatment
(p < .001). Pairwise comparisons of outcome measures
indicated that the completers did not improve on any
measure during the 2-week waiting period (baseline to
pre-CBT); this indicates the baseline stability of their
symptoms. On the other hand, the CBT intervention led
to significant reductions in all outcome measures at the
middle stage of treatment (pre–mid-CBT; p < .05) and a
further significant reduction after treatment completion
(mid–post-CBT; p < .05). On the basis of our primary
outcome measure (LSAS), 11 patients (73.3%) were
judged to be responders, and 6 of them (40%) met the
criteria for SAD remission at the post-CBT evaluation.
As shown in Table 3, our pre–post-CBT effect sizes
were large and provided comparable effectiveness to
those obtained in previous studies of individual CBT, as
determined using the model of Clark and Wells for all
social-severity scales (effect sizes for LSAS = 1.71, SPS =
0.96, SIAS = 1.80, FNE = 1.82 and FQ-SP = 1.54).
Predictors of CBT outcomes
None of the baseline demographic and clinical variables
(gender, age, SAD subtype, presence of comorbid major
depressive disorder, presence of another comorbid anx-
iety disorder, presence of avoidant personality disorder,
age of onset, duration of SAD, employment status, mari-
tal status, educational status, use of medication, and
presence of resistance to antidepressants) were signifi-
cant predictors of post-treatment LSAS score.
Discussion
This single-arm trial demonstrated that individual CBT,
which was originally developed in Western countries,
could lead to a significant reduction in SAD severity
among Japanese patients. Moreover, our individual CBT
demonstrated excellent acceptability, considering that
there was no dropout among the participants.
Although the severity of SAD among our recruited pa-
tients was higher than that observed in previous studies
(see Table 3), our effect size of 1.71 in terms of LSAS
scores between the pre- and post-CBT observations is
comparable to the effect sizes of 1.29–1.94 reported in
previous clinical trials on CBT that used the model of
Clark and Wells [28,29,37-39]. Comparison of effect sizes
among various studies may be difficult, because the LSAS
was administered by different methods (self-reported vs.
clinician-administered) across the different studies. How-
ever, it is thought to be possible to compare these different
types of LSAS scores, because scores on the self-report
version of the LSAS correspond well to those on the
clinician-administered version: In a previous study group,
there was little difference between the two versions of the
LSAS on any scale or subscale score [50].
Table 2 Repeated-measures analyses of variance (N = 15)
Baseline Pre-CBT Mid-CBT Post-CBT
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Time (F) η2
LSAS 90.5 (21.4)a 91.8 (23.5)a 72.3 (21.5)b 51.7 (27.8)c 27.3*** .66
SPS 42.4 (17.3)a 44.1 (18.7)a 32.8 (14.5)b 26.1 (17.6)c 18.9*** .57
SIAS 57.7 (11.9)a 58.7 (12.0)a 47.7 (13.6)b 37.1 (19.0)c 33.3*** .70
FNE 25.4 (3.9)a 25.2 (4.6)a 21.1 (6.2)b 16.9 (9.1)c 16.2*** .54
FQ-SP 25.4 (8.1)a 28.5 (8.2)a 19.9 (9.5)b 16.0 (10.1)c 15.9*** .54
*** Significant effect of time (p < .001).
Note: The same letters are not significantly different in pairwise comparisons.
Abbreviations: LSAS, Liebowitz Social Anxiety Scale; SPS, Social Phobia Scale; SIAS, Social Interaction Anxiety Scale; FNE, Fear of Negative Evaluation Scale; FQ-SP,
Fear Questionnaire – Social Phobia subscale.
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CBT showed that the observed baseline demographic
and clinical variables were not statistically significant
predictors of LSAS scores after receiving CBT. The pres-
ence of comorbid mood disorders did not predict CBT
outcomes in this study, and some previous studies have
also demonstrated that individuals with comorbid mood
disorders responded similarly to those with uncompli-
cated SAD [51,52]. However, Blanco (2003) found pre-
treatment levels of self-reported depression to be the
single most significant predictor of treatment outcomes
[53]. Thus, it may be necessary to assess the level of se-
verity of comorbid depression to facilitate the prediction
of CBT outcomes in further studies. As for antidepres-
sant history, it is reported that about 50% of individuals
do not respond to antidepressants or have residual
symptoms after first-line antidepressant treatment [54].
Most patients (73%) who participated in the current
study showed resistance to first-line medications (at least
one course of SSRI administration at the maximum dose
for at least 12 weeks). One reason for this pattern of re-
sults is that only SSRIs (fluvoxamine and paroxetine)
have been approved as treatments for SAD in Japan as
of 2012. However, in the present study, CBT de-
creased SAD severity similarly in antidepressant-Table 3 Comparison of effect sizes among various clinical tria
Study group Present study Clark et al. (2003) Stangier et al. (200
CBT protocol 90 min 14 weeks 75 min 16 weeks 60 min 15 weeks
































































Abbreviations: LSAS, Liebowitz Social Anxiety Scale; SPS, Social Phobia Scale; SIAS, S
Questionnaire – Social Phobia subscale; ES, Effect Size.resistant patients and antidepressant-responsive ones (i.
e., the presence of antidepressant resistance was not a
predictor of CBT outcomes). This finding suggested that
individual CBT might have potential as a next-step strat-
egy even for cases of antidepressant-resistant SAD.
Though the present study provided valuable informa-
tion, its design imposes the following limitations. (1) This
study included only a small sample size, which resulted in
limited generalizability of its conclusions. (2) This was a
single-center study; therefore, our participating population
was somewhat different from those seen in routine clinical
practice. Our study was designed to recruit patients simi-
lar to those seen in routine clinical practice; as a result,
40% had comorbid disorders, as is typical in clinical prac-
tice [55]. However, although the gender ratio of SAD cases
is not typically skewed, the participants in this study were
mostly women. The reason for this was that our out-
patient section always took appointments during the day-
time on weekdays; therefore, many men who worked
weekdays could not participate in this study. (3) The lack
of follow-up data limits the generalizability of the study’s
conclusions to longer-term outcomes. This is an import-
ant consideration in evaluating the effectiveness of CBT,
because CBT has unknown characteristics in terms
of longer-term effects, associated relapse rates, cost-ls using the model of Clark and Wells
3) Clark et al. (2006) Mörtberg et al. (2007) Stangier et al. (2011)
90 min0 14 weeks 60 min 16 weeks 50–90 min 20 weeks
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tion intake could not be discontinued before the start of
this study. Though the inclusion of subjects using psycho-
tropic medication limits the generalizability of the results,
most patients (73%) already showed resistance to first-line
medications (such as SSRIs) at baseline, and all of the pa-
tients showed baseline stability of their symptoms during
the 2-week waiting period. Thus, it seemed that our indi-
vidual CBT did indeed reduce SAD severity. (5) This was
an uncontrolled study; therefore, we could not conclude
definitively that our individual CBT was effective. It re-
mains unknown whether the observed improvement in
SAD severity is related to the natural course of SAD.
Future study should replicate these findings and ad-
dress the limitations of this study in multi-center, ran-
domized, controlled trials conducted with larger and
more diverse samples across longer follow-up periods.
Conclusions
Despite several limitations, this study suggests via a
single-arm design that individual CBT is a feasible treat-
ment, even for Japanese patients with SAD. Further con-
trolled trials that address the limitations of this study are
required.
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